Results 1 to 10 of about 2,515,873 (332)

Immune-Complex Mimics as a Molecular Platform for Adjuvant-Free Vaccine Delivery [PDF]

, 2013
Protein-based vaccine development faces the difficult challenge of finding robust yet non-toxic adjuvants suitable for humans. Here, using a molecular engineering approach, we have developed a molecular platform for generating self-adjuvanting immunogens
A Demissie, A Raja, A Regnault, A Williams, AF Cunningham, AN Antoniou, AR Berengian, AS Mustafa, B Heyman, BC Schalke, CK Kennaway, Craig van Dolleweerd, CT Cady, D Chargelegue, D Matheoud, DH Schuurhuis, E Celis, E Celis, EJ Wiersma, Elena Stylianou, EM Leyten, F Manca, F Pinheiro da Silva, F Villinger, F Winau, G Falero-Diaz, G Terres, GG Klaus, Gil Reynolds Diogo, H Boesen, Ilaria Pepponi, J Laissue, JM den Haan, Julian K.-C. Ma, K Osato, KB Reid, M Jacobsen, Matthew J. Paul, MF Bachmann, N Caccamo, N Polyanskaya, P Andersen, Pascal M. W. Drake, PD Simitsek, Pere-Joan Cardona, PM Guyre, PM Hogarth, PS Jackett, Q Li, R Jemmerson, R Pal, R Reljic, R Reljic, Rajko Reljic, RG Taylor, RJ Eisenberg, RJ Wilkinson, S Marusic-Galesic, SA Moreno-Mendieta, SA Plotkin, U Abdel-Motal, V Roupie, W Phoolcharoen, WE Houston, WR Heath, Y Yuan, Y Yuan, YM Wen, Z Chang   +68 more
core   +19 more sources

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

bioRxiv, 2021
Monoclonal antibodies and antibody cocktails are a promising therapeutic and prophylaxis for COVID-19. However, ongoing evolution of SARS-CoV-2 can render monoclonal antibodies ineffective.
Tyler N. Starr, Allison J. Greaney, A. Dingens, J. Bloom   +3 more
semanticscholar   +1 more source

Human monoclonal antibodies and monoclonal antibody multispecificity [PDF]

British Journal of Cancer, 1987
The majority of human anti-tumour monoclonal antibodies (Mabs) isolated to date have been disappointing. Firstly, they react or cross react with intracellular cytoskeletal proteins or nuclear antigens and therefore are of limited value as blood borne agents.
AM Campbell, P Whitford, RE Leake
openaire   +2 more sources

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

bioRxiv, 2020
The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 800 laboratory-confirmed human infections, including 25 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine.
Xiao-long Tian, Cheng Li, Ailing Huang, Shuai Xia, Sicong Lu, Zhènglì Shí, Lu Lu, Shibo Jiang, Zhenlin Yang, Yanling Wu, T. Ying   +10 more
semanticscholar   +1 more source

A human monoclonal antibody blocking SARS-CoV-2 infection

Nature Communications, 2020
The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking.
Chunyan Wang, Wentao Li, D. Drabek, Nisreen M. A. Okba, R. van Haperen, A. Osterhaus, F. V. van Kuppeveld, B. Haagmans, F. Grosveld, B. Bosch   +9 more
semanticscholar   +1 more source

Mediation Analyses for the Effect of Antibodies in Vaccination [PDF]

Journal of Causal Inference, 2024, 12:20220043, 2022
We review standard mediation assumptions as they apply to identifying antibody effects in a randomized vaccine trial and propose new study designs to allow identification of an estimand that was previously unidentifiable. For these mediation analyses, we partition the total ratio effect (one minus the vaccine effect) from a randomized vaccine trial ...
arxiv   +1 more source

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

New England Journal of Medicine, 2020
Background LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19).
J. Lundgren, B. Grund, C. Barkauskas, T. Holland, R. Gottlieb, U. Sandkovsky, Samuel M. Brown, K. Knowlton, W. Self, D. Files, M. Jain, T. Benfield, M. Bowdish, B. Leshnower, J. Baker, J. Jensen, E. Gardner, A. Ginde, E. Harris, I. Johansen, N. Markowitz, M. Matthay, L. Østergaard, Christina C. Chang, V. Davey, Anna Goodman, E. Higgs, Daniel D. Murray, T. A. Murray, R. Paredes, Mahesh K B Parmar, A. Phillips, C. Reilly, Shweta Sharma, R. Dewar, M. Teitelbaum, D. Wentworth, H. Cao, P. Klekotka, A. Babiker, A. Gelijns, V. Kan, M. Polizzotto, B. Thompson, H. Lane, J. Neaton   +45 more
semanticscholar   +1 more source

Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).

Asian Pacific Journal of Allergy and Immunology, 2020
Last decade witnessed the outbreak of many life-threatening human pathogens including Nipah, Ebola, Chikungunya, Zika, Middle East respiratory syndrome coronavirus (MERS-CoV), Severe Acute respiratory syndrome coronavirus (SARS-CoV) and more recently ...
B. Shanmugaraj, K. Siriwattananon, K. Wangkanont, W. Phoolcharoen   +3 more
semanticscholar   +1 more source

Systematic comparison of monoclonal versus polyclonal antibodies for mapping histone modifications by ChIP-seq. [PDF]

, 2016
BackgroundThe robustness of ChIP-seq datasets is highly dependent upon the antibodies used. Currently, polyclonal antibodies are the standard despite several limitations: They are non-renewable, vary in performance between lots and need to be validated ...
Busby, Michele, Cornett, Evan M, Epstein, Charles B, Farjoun, Yossi, Gienger, Elizabeth, Gladden, Adrianne, Goren, Alon, Li, Catherine, Nusbaum, Chad, Rothbart, Scott B, Xue, Catherine, Yofe, Ido   +11 more
core   +1 more source

Using cluster theory to calculate the experimental structure factors of antibody solutions [PDF]

, 2022
Monoclonal antibody solutions are set to become a major therapeutic tool in the years to come, capable of targeting various diseases by clever designing their antigen binding site. However, the formulation of stable solutions suitable for patient self-administration typically presents challenges, as a result of the increase in viscosity that often ...
arxiv   +1 more source